Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the quarter’s ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the ...

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have ...

In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase ...

This is the first economic evaluation of palonosetron. Although further research is needed to evaluate the economic impact of palonosetron-based regimens in a real-life context, the present ...

Palonosetron is clinically superior in controlling chemotherapy-induced nausea and vomiting, but how does its drug price ratio compare to other therapies?

Find the latest Supernus Pharmaceuticals, Inc. (SUPN) stock quote, history, news and other vital information to help you with your stock trading and investing.